The Efficacy and Safety of TBCB vs TBFB in Diagnosis of GGO

Shanghai Chest Hospital184 enrolled

Overview

The aim of this study is to investigate the difference of efficacy and safety between transbronchial cryobiopsy (TBCB) and transbronchial forceps biopsy (TBFB) in the diagnosis of lung ground-glass opacity.

The conventional biopsy method for lung ground-glass opacity (GGO) diagnosis is to use disposable guided sheath (including biopsy forceps and cell brushes) which have some limitations, such as big physical damage, small biopsy tissue, etc. Cryobiospy is a new technique for biopsy developed in recent years which has many advantages over conventional biopsy, such as larger tissue, higher diagnosis yield, less complication, etc. The investigators will explore the efficacy and safety of cryobiospy vs. biopsy forceps in GGO diagnosis. The study is designed as a prospective, randomized controlled trial, 184 patients will be expected to enroll in the study and receive EBUS examination before biopsy to check whether the GGO lesions exist or not. This is a parallel-control study that patients with GGO lesions will be randomized to either TBCB group or TBFB group for biopsy. The primary aim is to compare the diagnostic yields of the two biopsy techniques. The secondary endpoint is to assess the tissue size, sampling time, number of sampling and the quality of specimen.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

DIAGNOSTIC

Masking

SINGLE

Enrollment

184

Conditions

Lung Ground-Glass Opacity

Interventions

Transbronchial CryobiopsyPROCEDURE

The eligible patient will be randomized to TBCB group to receive transbronchial cryobiopsy.

Transbronchial Forceps BiopsyPROCEDURE

The eligible patient will be randomized to TBFB group to receive transbronchial forceps biopsy.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Male or female aged between 18 and 80. 2. CT or other imaging examination suggest a tendency towards malignant GGO (size ≥ 8 mm). The ground glass composition is more than 50%. 3. Thin-slice CT scan with bronchial access or adjacent lesions. 4. Multidisciplinary assessment suggest that bronchopulmonary biopsy is needed to identify the pathological features of GGO. 5. It is suitable for pathological biopsy by transbronchial cryobiopsy or forceps biopsy. 6. Ability to read, understand and sign ICF. Exclusion Criteria: 1. Disseminated GGO, suspected of benign or infectious lesions. 2. Preoperative imaging examination showed that the biopsy lesion was adjacent to the middle or large vessels. 3. There are contraindications for bronchoscopy, such as irreparable coagulation dysfunction, severe cardiopulmonary insufficiency. 4. Intolerance or difficulty in cooperating with bronchoscopy, etc. 5. Routine bronchoscopic abnormalities, such as endoscopic lesions, external pressure, mucosal lesions, stenosis, hemorrhage, etc. 6. Vulnerable groups, such as pregnant women, etc. 7. Some other special situations investigator consider subjects are not suitable to participant in this study.

Locations (1)

Shanghai Chest Hospital

Shanghai, Shanghai Municipality, China

Outcomes

Primary Outcomes

Diagnostic yield

Diagnostic yield of transbronchial cryobiopsy (TBCB) or transbronchial forceps biopsy (TBFB) for lung ground-glass opacity.

Time frame: Up to 6 Months

Secondary Outcomes

Tissue size

The maximum diameter measured by the biopsy tissue.

Time frame: Up to 1 months

Central Contacts

Jiayuan Sun, MD, PhD

CONTACT

+86-021-22200000 xkyyjysun@163.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.